This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices.
This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. It will be run from the Heart of England NHS Foundation Trust, which will provide the specialist input and oversight, and up to 40 practices across the Eastern Birmingham Health Organisation with approximately 2200 patients with COPD confirmed by their current medical practitioner. Each practice will be randomised to either the intervention or control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. Treatment will be at the discretion of the clinician and is not specified in the trial protocol. The investigators anticipate that the treatment recommendations in the intervention arm may include referral to pulmonary rehabilitation and reduction in the use of inhaled corticosteroids, which are prescribed at high rates in our locality. The control group will be seen by the usual staff at their practice. These patients will not be seen by the trial team and their data will be extracted remotely using electronic systems. The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices. Secondary outcomes will include: referral to secondary care, unscheduled healthcare consultations (ED attendance, hospital admissions), COPD exacerbations, healthcare costs, medications prescribed, biochemical markers of disease, radiological investigations, lung function tests measured when clinically indicated, and death within 12 month follow-up period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
1,000
The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
Usual standard of care
Dr. Sarah Pountain
Birmingham, West Midlands, United Kingdom
Rates of provision of guideline-based care in intervention and control practices for patients.
This will be done via the number of patients concordant with local guidelines (where care is defined by medication received and non-pharmacological interventions received, and they must receive smoking cessation, pulmonary rehabilitation, self-management plan and appropriate COPD medications in order to be guideline compliant)
Time frame: 1 Year
Referral Outcome
Referral to secondary care
Time frame: 1 Year
Unscheduled Outcome
Unscheduled healthcare consultations (ED attendance, hospital admissions)
Time frame: 1 Year
COPD Outcomes
COPD exacerbations
Time frame: 1 Year
Healthcare Outcomes
mean cost per patient in £ of the total cost of hospital attendances, GP visits, medications and vaccines during the study period
Time frame: 1 Year
Medications Outcomes
medications prescribed
Time frame: 1 Year
Biochemical markers of disease Outcomes
FBC, U\&E, LFT, CRP, AAT level/phenotype, and sputum culture results taken for patient
Time frame: 1 Year
Radiological Outcomes
number of CT scans or Chest X rays done
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 Year
Lung Function Outcomes
Lung function tests measured when clinically indicated, FEV1 (l) and FEV1 (% predicted), FEV1/FVC
Time frame: 1 Year
Death Outcome
Death within 12 month follow-up
Time frame: 1 Year